Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Scholler

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Journal of Clinical and Translational Science|November 29, 2023
Exercise as a community treatment for obesity and the metabolic disease epidemicJohn Scholler, Jeffrey S Otis
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept studyArchana Thakur, John Scholler, Dana L Schalk, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic CancerJohn Scholler, Ai Song, Mansi Deshmukh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 2009
Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophagesUnja Martin, John Scholler, Jesse Gurgel, et al.
Scientific Reports|February 7, 2024
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cellsDavid Mai, Tifara Boyce, Aakash Mehta, et al.
Science Advances|January 11, 2023
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinomaUgur Uslu, Tong Da, Charles-Antoine Assenmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2023
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cellsDavid Mai, Omar Johnson, Jordan Reff, et al.
Cell Reports|September 28, 2017
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18Biliang Hu, Jiangtao Ren, Yanping Luo, et al.
Frontiers in Immunology|July 22, 2021
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T CellsArchana Thakur, John Scholler, Ewa Kubicka, et al.
JCI Insight|June 17, 2020
A rational mouse model to detect on-target, off-tumor CAR T cell toxicityMauro Castellarin, Caroline Sands, Tong Da, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Journal of Clinical and Translational Science|November 29, 2023
Exercise as a community treatment for obesity and the metabolic disease epidemicJohn Scholler, Jeffrey S Otis
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept studyArchana Thakur, John Scholler, Dana L Schalk, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic CancerJohn Scholler, Ai Song, Mansi Deshmukh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 2009
Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophagesUnja Martin, John Scholler, Jesse Gurgel, et al.
Scientific Reports|February 7, 2024
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cellsDavid Mai, Tifara Boyce, Aakash Mehta, et al.
Science Advances|January 11, 2023
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinomaUgur Uslu, Tong Da, Charles-Antoine Assenmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2023
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cellsDavid Mai, Omar Johnson, Jordan Reff, et al.
Cell Reports|September 28, 2017
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18Biliang Hu, Jiangtao Ren, Yanping Luo, et al.
Frontiers in Immunology|July 22, 2021
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T CellsArchana Thakur, John Scholler, Ewa Kubicka, et al.
JCI Insight|June 17, 2020
A rational mouse model to detect on-target, off-tumor CAR T cell toxicityMauro Castellarin, Caroline Sands, Tong Da, et al.
Pageof 6